TX-MARY-KAY
17.5.2023 18:06:31 CEST | Business Wire | Press release
Mary Kay Inc., a global leader in skin care innovation, in partnership with the European Society for Dermatological Research, recently announced its inaugural Mary Kay Skin Health/Skin Disease Research Grant awardees at a special virtual event prior to the First International Societies for Investigative Dermatology conference in May. Grant recipients are researchers conducting groundbreaking, innovative studies in skin health and skin disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230517005040/en/
Mary Kay partnered with European Society for Dermatological Research (ESDR) to award inaugural Mary Kay-ESDR Skin Health/Skin Disease Research Grants. Congratulations to our 2022 recipients, Dr. Clarisse Ganier and Dr. Michael Cangkrama, who will each receive $20,000 grants to further their contributions in skin disease research. (Photo: Mary Kay Inc.)
“Mary Kay is dedicated to advancing skin and nutritional health research globally, and we know this cannot be done alone. Collaboration across industries, academic institutions, and clinicians is critical, which is why we are proud to partner with ESDR to furnish the first-ever Mary Kay-ESDR Skin Health/Skin Disease Research Grants,” said Dr. Lucy Gildea, Chief Innovation Officer, Product and Science at Mary Kay. “These grants bring this larger community together for new inspiration for the future, and Mary Kay is proud to be a part of this opportunity. We are excited to see how these recipients bring greater advancements to different aspects of skin health research.”
The Mary Kay Skin Health/Skin Disease Research Grants were announced at last year’s meeting in partnership with ESDR. The $20,000 grants were to be awarded to two researchers conducting incredible work in skin research to uncover new perspectives and invention strategies. In the months following the 2022 ESDR meeting, the company received applications from scientists across all of Europe.
The two grant awardees ultimately selected were:
- Dr. Michael Cangkrama, (Switzerland) Senior Scientist, Department of Biology, Institute of Molecular Health Sciences, ETH Zürich – Dr. Cangkrama is working on molecular and cellular mechanisms underlying the development and progression of epithelial skin cancers, the most common types of cancer in humans. His research projects will focus on investigating molecular mechanisms of squamous cancer development and the role of the tumor microenvironment using state-of-the-art approaches. He will utilize the grant to further develop his independent projects and continue to pursue positions as an independent group leader or Assistant Professor in Europe.
- Dr. Clarisse Ganier, (United Kingdom), Research Associate at the Center of Gene Therapy and Regenerative Medicine in King’s College London. Dr. Ganier is part of the Human Cell Atlas initiative – an international collaborative effort to map all cell types within the human body – to generate a comprehensive Skin Cell Atlas. As part of this work, they have created a multi-scale spatial atlas of healthy skin and basal cell carcinoma (BCC), incorporating single cell transcriptomics, in vivo optical coherence tomography, spatial global transcriptional profiling and in situ sequencing. Funding for this research will allow her to pursue her professional goals of starting her own laboratory focusing on skin cancer biology by combining multiomics data, both in vitro and ex vivo.
“Congratulations to each of our 2022 grant award recipients,” added Dr. Gildea. “These individuals were carefully chosen in collaboration with the European Society for Dermatological Research—and we are thrilled to support their research.”
“On behalf of the ESDR board, we would like to thank Mary Kay for its support of the ESDR and congratulate this year’s grant recipients for their tremendous contributions to their respective fields. A key objective of our Society is to promote innovative research in investigative dermatology and to support researchers' activities in translational skin research,” said Eli Sprecher, Chair, Scientific Program Committee of ESDR.
The sponsorship and grants, revealed leading up to the inaugural International Societies for Investigative Dermatology Conference in Tokyo, are just the latest efforts by Mary Kay to reinforce the company’s long-standing commitment to advancing skin health research and development. Mary Kay holds more than 1,600 patents for products, technologies and packaging designs in its global portfolio.
View the full Mary Kay-ESDR Skin Health/Skin Disease Research Grants Ceremony recording here.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in more than 35 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.
About European Society for Dermatological Research (ESDR)
The European Society for Dermatological Research (ESDR), founded in 1970, is a non-profit organization promoting basic and clinical science related to dermatology. The ESDR is the largest investigative dermatology society in Europe with a current membership of about 1100. By supporting investigative dermatology and skin research, the ESDR contributes to an in-depth understanding of skin homeostasis and toward improving the health of patients suffering from skin and venereal diseases. The ESDR facilitates the exchange of information relevant to investigative dermatology between clinicians and scientists worldwide. The ESDR also organizes educational events throughout the year to further knowledge in dermatological research. For more information, please visit: https://esdr.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005040/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen offentliggør regnskab for fjerde kvartal og helåret 202510.3.2026 19:52:00 CET | Pressemeddelelse
Andersen Group Inc. (NYSE: ANDG) ("Andersen"), en førende udbyder af uafhængig rådgivning inden for skat, vurdering og finans til private kunder og familiekontorer, virksomheder og fonde i USA, vil offentliggøre sine finansielle resultater for hele året og fjerde kvartal 2025 efter børslukketid tirsdag den 17. marts 2026. Andersens administrerende direktør og bestyrelsesformand, Mark L. Vorsatz, og Andersens økonomidirektør, Neal Livingston, vil afholde en telekonference for at fremlægge Andersens økonomiske resultater tirsdag den 17. marts 2026 kl. 17.00 ET. Deltagere kan følge webcasten på https://event.choruscall.com/mediaframe/webcast.html?webcastid=J3Hvslre. Et link til optagelsen af webcasten vil kunne findes på Andersens Investor Relations-webside på investor.andersen.com inden for et par timer efter begivenheden og vil være tilgængeligt på websiden i seks måneder. Om Andersen Andersen er en førende udbyder af uafhængig rådgivning inden for skat, vurdering og finans til private
Xtep-Sponsored Chinese Teenage Dancer Claims World Championship at Juste Debout Street Dance World Finals10.3.2026 19:46:00 CET | Press release
Xtep, a well-known sportswear brand from China, proudly announced that Xtep-sponsored Chinese teenage dancers delivered an electrifying performance at the Juste Debout Street Dance World Finals in Paris on Sunday, March 8, 2026, claiming top honors and showcasing a unique fusion of traditional Chinese culture with modern street dance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310519224/en/ Chinese Teens Dance to Glory at Juste Debout World Finals Li Yongqiu, a 14-year-old from Southwestern China’s Chongqing Municipality, made history by winning the Global Championship in the Junior Dance Tour, becoming the third Chinese dancer to achieve this feat. His explosive power and technical mastery, honed through years of training that integrates Kungfu elements, captivated judges and audiences alike. The Chinese contingent's success didn't stop there. Zhang Xinlan and Zhang Chuyi secured a Top 8 finish in the Popping Adult D
ATLAS Infrastructure Invests in H2O America, Backs Long-Term Growth Strategy10.3.2026 18:29:00 CET | Press release
ATLAS anchors H2O America’s equity raise and establishes new substantial shareholdingUpsized transaction highlights strong market support for H2O’s long-term strategy and sector leading growth outlookH2O’s organic growth fully equity funded into 20281 ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing funds on behalf of long-term infrastructure clients. Following the recent equity placement, ATLAS’s actively managed accounts hold ~10.8% voting and economic interest in H2O America (“H2O”). ATLAS was pleased to support H2Os long‑term strategy to invest in local water and wastewater utility operations through our participation in the recent equity raise. ATLAS recognises the disciplined approach from H2O management which focuses on organic investment in existing businesses alongside targeted and accretive transactions such as the acquisition of Quadvest which materially expands H2O’s regulated water footprint in a premium high‑growth jurisdiction
TIXiMED Announces Promising Preclinical Data: Oral TIX100 Prevents Weight Regain After GLP-1 Cessation in Obesity Model10.3.2026 18:22:00 CET | Press release
TIX100 prevented weight regain in mice after semaglutide discontinuation Supports potential role as oral weight maintenance therapy following GLP-1 Receptor Agonist (GLP-1) treatment, addressing a major challenge in long-term obesity management TIXiMED, Inc., a clinical-stage pharmaceutical company developing a novel oral therapy targeting thioredoxin-interacting protein (TXNIP) for diabetes and metabolic disorders, is pleased to highlight new research by investigators at the University of Alabama at Birmingham (UAB) Comprehensive Diabetes Center. The study demonstrates that its oral compound, TIX100, effectively prevents weight rebound following discontinuation of GLP-1 treatment in a mouse model of diet-induced obesity. In the study, mice treated with semaglutide experienced significant weight loss of over 13% body weight during a 2-week treatment period while continuing a high-fat diet. Upon discontinuation of semaglutide, untreated mice rapidly regained 14% of their body weight, mi
Svante and Integrated Packaging Company Advance U.S. Biogenic CDR Project to Feasibility10.3.2026 14:57:00 CET | Press release
The bioenergy with carbon capture (BECCS) project aims to remove more than 500,000 tonnes per year of biogenic CO2 emissions from a U.S. paper mill’s recovery boiler Svante Development Inc. is co-investing to advance the project The project will generate high-quality carbon dioxide removal (CDR) credits to market to Voluntary Carbon Market (VCM) buyers. Svante Technologies Inc. (“Svante”) announced today that its bioenergy with carbon capture and storage (BECCS) project at a paper mill in the Southeast U.S. has progressed to the feasibility study phase. The project is being developed in partnership with an integrated sustainable packaging company, following an extensive screening and pre-feasibility study conducted across several of the partner’s mills. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310319382/en/ During the feasibility study phase, the companies will complete further engineering and design activities, cos
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom